NEWS
NEWARK, CA • FEBRUARY 26, 2024
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs), today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.
© Copyright AceLink Therapeutics. All rights reserved